Delving into the Latest Updates on Diphtheria-tetanus vaccine(Finlay Institute) with Synapse

Overview

Basic Info

Drug Type

Combination vaccine, Prophylactic vaccine, Toxoid vaccine

Synonyms

dT

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesOther Diseases

Active Indication

DiphtheriaTetanus

Inactive Indication-

Originator Organization

Finlay Institute of Cuba

Active Organization

Finlay Institute of Cuba

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Cuba (01 Jan 2006),

DiphtheriaTetanus

Regulation-

Login to view timeline

A phase III, open, randomised, multicentre study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ combined reduced antigen content diphtheria-tetanus toxoids and acellular pertussis vaccine (Boostrix™) and the Chinese DT vaccine, when administered as booster vaccination in healthy children aged 6-8 years who were previously vaccinated with four doses of combined diphtheria-tetanus-pertussis (DTP) vaccine in the first two years of life. - dTpa-038

Start Date-

Sponsor / Collaborator

GlaxoSmithKline LLC

IRCT138812093454N1

/ CompletedPhase 2IIT

The evaluation of effectiveness of dT vaccine on immune response to HB vaccine in non responder dialysis patients

Start Date15 Mar 2009

Sponsor / Collaborator

Isfahan University of Medical Sciences

100 Clinical Results associated with Diphtheria-tetanus vaccine(Finlay Institute)

Login to view more data

100 Translational Medicine associated with Diphtheria-tetanus vaccine(Finlay Institute)

Login to view more data

100 Patents (Medical) associated with Diphtheria-tetanus vaccine(Finlay Institute)

Login to view more data

71

Literatures (Medical) associated with Diphtheria-tetanus vaccine(Finlay Institute)

01 Jan 2025·Lung Cancer

Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort

Article

Author: Couraud, Sébastien ; Tomasini, Pascale ; Pichon, Eric ; Auliac, Jean-Bernard ; Swalduz, Aurélie ; Fabre, Elizabeth ; Wislez, Marie ; Mazieres, Julien ; Geier, Margaux ; Missy, Pascale ; Debieuvre, Didier ; Lerolle, Ulrike ; Domblides, Charlotte ; Cortot, Alexis ; Larivé, Sébastien ; Daniel, Catherine ; Planchard, David ; Fallet, Vincent ; Beau-Faller, Michèle ; Westeel, Virginie ; Bayle-Bleuez, Sophie ; Morin, Franck

BACKGROUNDBRAF V600E mutations occur in 2-5 % of advanced non-small cell lung cancer (NSCLC) patients. The dabrafenib-trametinib (D-T) combination was associated with improved and durable OS in patients in phase II. This study (IFCT-2004 BLaDE study) reported the efficacy of D-T combination in a large retrospective French real-world multicenter cohort of patients with advanced BRAF V600E-mutated NSCLC.METHODPatients with advanced BRAF V600E-mutated NSCLC diagnosed between 01.01.2016 and 31.12.2019 and treated with D-T in combination, regardless of the treatment line, were included. The primary endpoint was the 12-month OS rate (%) in patients receiving D-T as a second-line therapy or beyond.RESULTSA total of 163 patients were included: 50.3 % were female, 30.2 % were never smokers, 95.1 % had adenocarcinoma, and 78.2 % had a PDL1 ≥ 1 %. The median age was 68.3 years. At D-T initiation, 80.8 % of patients had a PS of 0/1, 78.6 % had stage IV disease, and 20.9 % had brain metastasis. At the cutoff, the median follow-up was 27.4 months. The 12-month OS rate in patients receiving D + T as a second-line therapy or beyond (n = 119) was 67.4 %, with a median progression-free survival (mPFS) of 10.4 months. Among the 44 patients who received D + T as a first-line therapy, the 12-month OS rate was 67.4 %, with an mPFS of 18.2 months. D-T discontinuation for toxicity was reported in 10.3 % of patients.CONCLUSIONSTo our knowledge, this is the largest retrospective cohort of BRAF-mutated patients reported. The findings confirmed the significant efficacy of D-T in combination with BRAF V600E-mutated metastatic NSCLC in pretreated and untreated patients. These results under real-world conditions are consistent with those of other registered studies.

01 Aug 2024·Vaccine

Impact of the emergence of severe acute respiratory syndrome coronavirus 2 omicron variants on routine childhood immunization in Japan

Article

Author: Aizawa, Yuta ; Sasagawa, Fujio ; Saitoh, Akihiko ; Sato, Isamu ; Abe, Yuki

BACKGROUNDThe coronavirus disease 2019 (COVID-19) pandemic disrupted routine childhood vaccination worldwide, especially at the beginning of the pandemic. After the emergence of variants of concern, particularly the Omicron variants, the number of COVID-19 cases significantly increased, especially in children. However, the impact of the Omicron variants on routine childhood vaccination is unknown.METHODSThis retrospective observational study collected data on vaccines included in the Japanese national immunization program (NIP) of children 15 years or younger between 2016 and 2022 in Niigata, Japan. During the study period, hepatitis B virus vaccine and rotavirus vaccines were introduced to the NIP in October 2016 and October 2020, respectively. The monthly number of vaccine doses per eligible child population between 2020 and 2022 (pandemic period) was compared to the average number of vaccine doses in the corresponding month between 2016 and 2019 (pre-pandemic period). The effect of 8 surges of COVID-19 patients on trends in routine childhood vaccination was also analyzed.RESULTSThe numbers of doses during the pre-Omicron pandemic period were comparable to the values administered before the pandemic. However, after the emergence of the Omicron variants, and especially after the surge of Omicron variant BA.5 in 2022, the number of vaccine doses declined. The decline was notable in second doses of MR vaccine at age 5-6 years by - 9.6 % and diphtheria-tetanus vaccine at ages 11-12 years by - 14.1 %.CONCLUSIONSRoutine childhood immunization was significantly affected by the emergence of the Omicron variants most likely due to the facts that more candidates and their guardians contracted COVID-19, or were required isolation for close contacts. The findings highlight the importance of continued monitoring to maintain high coverage of routine childhood immunizations for controlling vaccine preventable diseases. A follow-up study should investigate changes in the number of declined vaccine doses during Omicron variant predominance.

01 Jan 2024·Infection & Chemotherapy

Recommendations for Adult Immunization by the Korean Society of Infectious Diseases, 2023: Minor Revisions to the 3rd Edition

Review

Author: Baek, Jihyeon ; Cheong, Hee Jin ; Han, Sang Hoon ; Choo, Eun Ju ; Kim, Woo Joo ; Choi, Jun Yong ; Lee, Dong-Gun ; Chin, BumSik ; Choi, Jung-Hyun ; Choi, Won Suk ; Lee, Mi Suk ; Park, Wan Beom ; Kwon, Ki Tae ; Song, Joon Young ; Choi, Young Hwa ; Choi, Hee-Jung ; Lee, Hyo-Jin ; Lee, Jin-Soo ; Yeom, Joon Sup

The Korean Society of Infectious Diseases has been regularly developing guidelines for adult immunization since 2007. In 2023, the guidelines for the following seven vaccines were revised: influenza, herpes zoster, pneumococcal, tetanus-diphtheria-pertussis (Tdap), human papillomavirus (HPV), meningococcal, and rabies vaccines. For the influenza vaccine, a recommendation for enhanced vaccines for the elderly was added. For the herpes zoster vaccine, a recommendation for the recombinant zoster vaccine was added. For the pneumococcal vaccine, the current status of the 15-valent pneumococcal conjugate vaccine and 20-valent PCV was described. For the Tdap vaccine, the possibility of using Tdap instead of tetanus-diphtheria vaccine was described. For the HPV vaccine, the expansion of the eligible age for vaccination was described. For the meningococcal vaccine, a recommendation for the meningococcal B vaccine was added. For the rabies vaccine, the number of pre-exposure prophylaxis doses was changed. This manuscript documents the summary and rationale of the revisions for the seven vaccines. For the vaccines not mentioned in this manuscript, the recommendations in the 3rd edition of the Vaccinations for Adults textbook shall remain in effect.

100 Deals associated with Diphtheria-tetanus vaccine(Finlay Institute)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07AM51	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diphtheria	Cuba	Finlay Institute of Cuba	01 Jan 2006
Tetanus	Cuba	Finlay Institute of Cuba	01 Jan 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2015	Not Applicable	HER2 Positive Breast Cancer Neoadjuvant	64	Docetaxel plus trastuzumab (DT)	(omgkvgypir) = To date, median survival has not been reached nrxoaabovn (rqjiiisfug )	-	20 May 2015
				DT plus carboplatin (DTP)